Drugs / Octaplas SD
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01063595 Comparator | Dec 2009 → Jul 2010 | — | Octapharma | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Octaplas SD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01063595 ↗ |
| Modality | Other / unclassified | “Octaplas SD was composed of human coagulation-active plasma” NCT01063595 ↗ |
| Route | Intravenous | “Participants received 1200 mL of Octaplas SD intravenously once.” NCT01063595 ↗ |